A Study of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Diet/Exercise Therapy (0431-054)(COMPLETED)
Primary Purpose
Diabetes Mellitus, Non-Insulin-Dependent
Status
Completed
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
sitagliptin phosphate
Comparator: voglibose
Sponsored by

About this trial
This is an interventional treatment trial for Diabetes Mellitus, Non-Insulin-Dependent
Eligibility Criteria
Inclusion Criteria:
- Patients have type 2 diabetes mellitus on diet/exercise therapy
Exclusion Criteria:
- Patients have type 1 diabetes mellitus
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Sitagliptin 50 mg QD
Voglibose 0.2 mg TID
Arm Description
sitagliptin 50 mg orally once daily (QD=once daily)
voglibose 0.2 mg orally three times daily (TID= three times daily)
Outcomes
Primary Outcome Measures
Change From Baseline in HbA1c at Week 12
HbA1c is measured as a percent. Thus, this change from baseline reflects the Week 12 HbA1c percent minus the Week 0 HbA1c percent.
Secondary Outcome Measures
Change From Baseline in Fasting Plasma Glucose at Week 12
Change from baseline at Week 12 is defined as fasting plasma glucose at Week 12 minus fasting plasma glucose at Week 0.
Change From Baseline in 2 Hour Postprandial Glucose at Week 12
Change from baseline at Week 12 is defined as 2-hour postprandial glucose Week 12 minus 2-hour postprandial glucose Week 0.
Full Information
NCT ID
NCT00411554
First Posted
December 13, 2006
Last Updated
February 3, 2016
Sponsor
Merck Sharp & Dohme LLC
1. Study Identification
Unique Protocol Identification Number
NCT00411554
Brief Title
A Study of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Diet/Exercise Therapy (0431-054)(COMPLETED)
Official Title
Sitagliptin (MK0431) Phase III Double-blind Comparative Study - Type 2 Diabetes Mellitus -
Study Type
Interventional
2. Study Status
Record Verification Date
February 2016
Overall Recruitment Status
Completed
Study Start Date
January 2007 (undefined)
Primary Completion Date
August 2007 (Actual)
Study Completion Date
August 2007 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Merck Sharp & Dohme LLC
4. Oversight
5. Study Description
Brief Summary
The clinical study determines the safety and efficacy of Sitagliptin (MK0431) in patients with type 2 diabetes mellitus who have inadequate glycemic control on diet/exercise therapy.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Non-Insulin-Dependent
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
319 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Sitagliptin 50 mg QD
Arm Type
Experimental
Arm Description
sitagliptin 50 mg orally once daily (QD=once daily)
Arm Title
Voglibose 0.2 mg TID
Arm Type
Active Comparator
Arm Description
voglibose 0.2 mg orally three times daily (TID= three times daily)
Intervention Type
Drug
Intervention Name(s)
sitagliptin phosphate
Other Intervention Name(s)
MK0431
Intervention Description
sitagliptin 50 mg orally once daily QD. Duration of Treatment: 12 Weeks
Intervention Type
Drug
Intervention Name(s)
Comparator: voglibose
Other Intervention Name(s)
voglibose
Intervention Description
voglibose 0.2 mg orally three times daily TID. Duration of Treatment: 12 Weeks
Primary Outcome Measure Information:
Title
Change From Baseline in HbA1c at Week 12
Description
HbA1c is measured as a percent. Thus, this change from baseline reflects the Week 12 HbA1c percent minus the Week 0 HbA1c percent.
Time Frame
Baseline and Week 12
Secondary Outcome Measure Information:
Title
Change From Baseline in Fasting Plasma Glucose at Week 12
Description
Change from baseline at Week 12 is defined as fasting plasma glucose at Week 12 minus fasting plasma glucose at Week 0.
Time Frame
Baseline and Week 12
Title
Change From Baseline in 2 Hour Postprandial Glucose at Week 12
Description
Change from baseline at Week 12 is defined as 2-hour postprandial glucose Week 12 minus 2-hour postprandial glucose Week 0.
Time Frame
Baseline and Week 12
10. Eligibility
Sex
All
Minimum Age & Unit of Time
20 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients have type 2 diabetes mellitus on diet/exercise therapy
Exclusion Criteria:
Patients have type 1 diabetes mellitus
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Medical Monitor
Organizational Affiliation
Merck Sharp & Dohme LLC
Official's Role
Study Director
12. IPD Sharing Statement
Citations:
PubMed Identifier
20590736
Citation
Iwamoto Y, Tajima N, Kadowaki T, Nonaka K, Taniguchi T, Nishii M, Arjona Ferreira JC, Amatruda JM. Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial. Diabetes Obes Metab. 2010 Jul;12(7):613-22. doi: 10.1111/j.1463-1326.2010.01197.x.
Results Reference
result
Learn more about this trial
A Study of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Diet/Exercise Therapy (0431-054)(COMPLETED)
We'll reach out to this number within 24 hrs